TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
-9.4%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.21B
AUM Growth
-$432M
(-16%)
Cap. Flow
-$82.9M
Cap. Flow
% of AUM
-3.75%
Top 10 Holdings %
Top 10 Hldgs %
42.68%
Holding
227
New
13
Increased
52
Reduced
76
Closed
10
Top Buys
| 1 |
Biogen
BIIB
|
+$15.1M |
| 2 |
Centene
CNC
|
+$8.24M |
| 3 |
Moderna
MRNA
|
+$7.61M |
| 4 |
Eli Lilly
LLY
|
+$6.73M |
| 5 |
Sanofi
SNY
|
+$6.15M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$14.8M |
| 2 |
Merck
MRK
|
+$14.5M |
| 3 |
MDCO
Medicines Co
MDCO
|
+$10.3M |
| 4 |
Johnson & Johnson
JNJ
|
+$10.2M |
| 5 |
Pfizer
PFE
|
+$8.65M |
Sector Composition
| 1 | Healthcare | 95.66% |
| 2 | Real Estate | 2.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Acadia Healthcare
ACHC
$2.08B
| $2.41M | 0.11% |
131,200
-5,000
| -4% | -$91.8K |
|
127
Charles River Laboratories
CRL
$7.97B
| $2.33M | 0.11% |
18,467
-2,500
| -12% | -$316K |
|
128
Philips
PHG
$26.7B
| $2.24M | 0.1% |
67,683
+15,886
| +31% | +$526K |
|
129
Ligand Pharmaceuticals
LGND
$3.23B
| $2.23M | 0.1% |
49,036
-16,615
| -25% | -$754K |
|
|
ICPT
130
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2.17M | 0.1% |
34,414
| – | – |
|
131
Arrowhead Research
ARWR
$3.76B
| $2.13M | 0.1% |
74,186
-31,212
| -30% | -$898K |
|
132
uniQure
QURE
$960M
| $2.08M | 0.09% |
43,849
-27,342
| -38% | -$1.3M |
|
133
Y-mAbs Therapeutics
YMAB
$390M
| $2M | 0.09% |
76,548
+65,222
| +576% | +$1.7M |
|
|
ENDP
134
DELISTED
Endo International plc
ENDP
| $1.97M | 0.09% |
531,570
| – | – |
|
135
Zai Lab
ZLAB
$3.49B
| $1.93M | 0.09% |
37,523
| – | – |
|
136
Alcon
ALC
$39B
| $1.86M | 0.08% |
36,686
-18,683
| -34% | -$949K |
|
137
Axsome Therapeutics
AXSM
$6.45B
| $1.86M | 0.08% |
+31,591
| New | +$1.86M |
|
138
Bausch Health
BHC
$2.71B
| $1.84M | 0.08% |
118,412
-20,400
| -15% | -$316K |
|
139
Coherus Oncology, Inc. Common Stock
CHRS
$159M
| $1.81M | 0.08% |
111,663
-13,483
| -11% | -$219K |
|
|
TRIL
140
DELISTED
Trillium Therapeutics Inc.
TRIL
| $1.81M | 0.08% |
448,049
+1,950
| +0.4% | +$7.88K |
|
|
GMRE
141
Global Medical REIT
GMRE
$509M
| $1.77M | 0.08% |
174,897
+56,805
| +48% | +$575K |
|
142
Align Technology
ALGN
$9.85B
| $1.75M | 0.08% |
10,041
-12,337
| -55% | -$2.15M |
|
143
Healthcare Realty
HR
$6.4B
| $1.72M | 0.08% |
70,662
+24,662
| +54% | +$599K |
|
|
RARX
144
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $1.72M | 0.08% |
35,743
-20,086
| -36% | -$964K |
|
145
Quest Diagnostics
DGX
$20.4B
| $1.69M | 0.08% |
21,025
| – | – |
|
146
AnaptysBio
ANAB
$621M
| $1.67M | 0.08% |
118,261
| – | – |
|
147
Guardant Health
GH
$7.5B
| $1.65M | 0.07% |
23,656
+19,323
| +446% | +$1.34M |
|
148
Insmed
INSM
$31B
| $1.58M | 0.07% |
98,387
-66,399
| -40% | -$1.06M |
|
149
Steris
STE
$24.5B
| $1.57M | 0.07% |
11,218
-3,572
| -24% | -$500K |
|
150
Heron Therapeutics
HRTX
$199M
| $1.54M | 0.07% |
131,183
+71,341
| +119% | +$837K |
|